National Institute on Ageing
DONATE JOIN OUR MAILING LIST
ABOUT US Our Team Fellows Advisory Board Partners Contact
Reports Ageing in the Right Place Ageing Beyond Borders Decade of Healthy Ageing Resources National Seniors Strategy Pension Centre of Excellence Centre d’excellence des pensions Slaight Foundation Partners
Media Releases & Announcements Commentary Newsletters The NIA & Toronto Star's Third Act Featured News
Upcoming Events Past Events
Current Openings Canadian Leadership in Ageing Awards Journalism in Ageing Fellowships Journalism in Ageing Project
ABOUT NIA ABOUT US Our Team Fellows Advisory Board Partners Contact OUR WORK Reports Ageing in the Right Place Ageing Beyond Borders Decade of Healthy Ageing Resources National Seniors Strategy Pension Centre of Excellence Centre d’excellence des pensions Slaight Foundation Partners News Media Releases & Announcements Commentary Newsletters The NIA & Toronto Star's Third Act Featured News EVENTS Upcoming Events Past Events
National Institute on Ageing
Opportunities Current Openings Canadian Leadership in Ageing Awards Journalism in Ageing Fellowships Journalism in Ageing Project DONATEJOIN OUR MAILING LIST
The Beacon Herald – May 21, 2020

Health Canada clears Appili Therapeutics’ phase 2 clinical trial evaluating Favipiravir as prophylactic agent against COVID-19 outbreaks

The National Institute on Ageing has estimated that as of May 6, 2020, 82 percent of deaths related to COVID-19 in Canada were associated with long-term care facilities.

Learn More>

Hyallan BaeMay 29, 2020spr4
Facebook0 Twitter Pinterest0 0 Likes
Previous

SickBoy Podcast – May 22, 2020

Hyallan BaeMay 29, 2020spr5
Next

iPolitics – May 20, 2020

i PoliticsHyallan BaeMay 29, 2020spr4
 

National Institute on Ageing
Ted Rogers School of Management
Toronto Metropolitan University (formerly Ryerson University)

350 Victoria St.
Toronto, Ontario
M5B 2K3
Canada 

Contact Us

info.nia@torontomu.ca